Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 1;10(12):3103.
doi: 10.3390/biomedicines10123103.

Glial Contributions to Lafora Disease: A Systematic Review

Stefania Della Vecchia  1 , Maria Marchese  2 , Filippo Maria Santorelli  1   2
Affiliations
Review

Glial Contributions to Lafora Disease: A Systematic Review

Stefania Della Vecchia et al. Biomedicines. .

Abstract

Background: Lafora disease (LD) is a neurodegenerative condition characterized by the accumulation of polyglucosan bodies (PBs) throughout the brain. Alongside metabolic and molecular alterations, neuroinflammation has emerged as another key histopathological feature of LD.

Methods: To investigate the role of astrocytes and microglia in LD, we performed a systematic review according to the PRISMA statement. PubMed, Scopus, and Web-of-Science database searches were performed independently by two reviewers.

Results: Thirty-five studies analyzing the relationship of astrocytes and microglia with LD and/or the effects of anti-inflammatory treatments in LD animal models were identified and included in the review. Although LD has long been dominated by a neuronocentric view, a growing body of evidence suggests a role of glial cells in the disease, starting with the finding that these cells accumulate PBs. We discuss the potential meaning of glial PB accumulations, the likely factors activating glial cells, and the possible contribution of glial cells to LD neurodegeneration and epilepsy.

Conclusions: Given the evidence for the role of neuroinflammation in LD, future studies should consider glial cells as a potential therapeutic target for modifying/delaying LD progression; however, it should be kept in mind that these cells can potentially assume multiple reactive phenotypes, which could influence the therapeutic response.

Keywords: Lafora disease; astrocytes; epilepsy; microglia; neurodegeneration; neuroinflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow chart of the review process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Minassian B.A., Lee J.R., Herbrick J.A., Huizenga J., Soder S., Mungall A.J., Dunham I., Gardner R., Fong C.Y., Carpenter S., et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. 1998;20:171–174. doi: 10.1038/2470. - DOI - PubMed
    1. Chan E.M., Young E.J., Ianzano L., Munteanu I., Zhao X., Christopoulos C.C., Avanzini G., Elia M., Ackerley C.A., Jovic N.J., et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat. Genet. 2003;35:125–127. doi: 10.1038/ng1238. - DOI - PubMed
    1. Moreno D., Towler M.C., Hardie D.G., Knecht E., Sanz P. The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits. Mol. Biol. Cell. 2010;21:2578–2588. doi: 10.1091/mbc.e10-03-0227. - DOI - PMC - PubMed
    1. Sullivan M.A., Nitschke S., Steup M., Minassian B.A., Nitschke F. Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan. Int. J. Mol. Sci. 2017;18:1743. doi: 10.3390/ijms18081743. - DOI - PMC - PubMed
    1. Turnbull J., Tiberia E., Striano P., Genton P., Carpenter S., Ackerley C.A., Minassian B.A. Lafora disease. Epileptic Disord. 2016;18:38–62. doi: 10.1684/epd.2016.0842. - DOI - PMC - PubMed